Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

National Institutes of Health Announces New Program To Develop Therapeutics For Rare And Neglected Diseases
The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases Program, or TRND.

NHS Finances In Better Shape But Action Needed Now To Prepare For Leaner Years From 2011, UK
Commenting in response to the Public Accounts Select Committee report into financial management in the NHS, which highlighted the service had a ÷£1.7 billion surplus at the end of 2007/8, The King"s Fund"s Chief Executive Niall Dickson said:
News of the day
OSI Pharmaceuticals Announces Acceptance Of Tarceva Supplemental New Drug Application For Review By The U.S. Food And Drug Administration
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental New Drug Application (sNDA) for the use of Tarceva® (erlotinib) as a first-line maintenance treatment for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy. Based upon the March 17th receipt of filing the FDA Prescription Drug Fee Act (PDUFA) review date will be on or about January 18, 2010.
Sexual Health

Impax Receives FDA Approval For Generic Precose(R) Tablets, 25 Mg, 50 Mg And 100 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) confirmed that the U.S. Food and Drug Administration (FDA) has granted approval of the Company"s Abbreviated New Drug Application (ANDA) for generic versions of Precose® Tablets (acarbose), 25 mg, 50 mg and 100 mg strengths. Precose®, a Bayer HealthCare Pharmaceuticals product, is used in the management of type two diabetes mellitus. The Company expects to launch all strengths in the fourth quarter of 2009, through Global Pharmaceuticals, Impax"s generic division. According to Wolters Kluwer Health, U.S. generic and brand sales for Acarbose 25 mg, 50 mg and 100 mg tablets were approximately $32 million for the 12 months ended March 2009. Impax Laboratories, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009